Biophytis SaEURONEXT: ALBPS

Biophytis S A to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity

· Issued by Biophytis SA

09 Sep 2026 07:00 CEST

Subscribe
Issuer

BIOPHYTIS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1432691_PR__ANVISA_amendment_090926_Final.pdf

Source

Biophytis

Provider

Les Echos

Company Name

BIOPHYTIS

ISIN

FR001400OLP5

Symbol

ALBPS

Market

Euronext Growth

Company press releases subscription ×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in your account section or create an account.
Cancel

Earlier from Biophytis Sa

All Biophytis Sa news releases